[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hysterectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hysterectomy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,41,67,93,138,171,205,224,253,278,307,329,357,385,403,428,459,480,500,530,560,587,611],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100591499","pvi-predictors-in-laparoscopic-hysterectomy-100591499",false,"NCT06981221","PVI Predictors in Laparoscopic Hysterectomy","Predictors of Pleth Variability Index During Laparoscopically Assisted Vaginal Hysterectomy","Inclusion Criteria:\n\n* adult females aged 19-70 years (American Society of Anesthesiologists physical status I-III) scheduled for elective LAVH.\n\nExclusion Criteria:\n\n* emergency surgery, severe cardiac or pulmonary disease, renal failure, pregnancy, or conditions contraindicating fluid administration. Participants were consecutively recruited during preoperative consultations.","FEMALE","19 Years","70 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","This observational study investigates the predictors of Pleth Variability Index (PVI) changes in euvolemic patients undergoing laparoscopic-assisted vaginal hysterectomy (LAVH). The primary objective is to quantify changes in PVI (ΔPVI) across six intraoperative time points associated with positional shifts. Secondary objectives include identifying key predictors of significant PVI change (ΔPVI ≥ 5%), such as passive leg raising, Trendelenburg position, body mass index (BMI), and intraabdominal pressure. Additional variables including perfusion index, mean arterial pressure, bispectral index, skin temperature, age, and anesthetic agent will be evaluated as potential modulators. Findings aim to support individualized fluid management strategies in LAVH.",[25,26,27],"Hysterectomy","PVI","Fluid Responsiveness","RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":21},"2026-07-01",{"date":36,"type":21},"2026-08-20",{"name":38,"class":39},"Wonkwang University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100630093","effectiveness-of-thoracoabdominal-nerve-block-m-tapa-on-postoperative-pain-relief-in-laparoscopic-hysterectomy-100630093","NCT07483190","Effectiveness of Thoracoabdominal Nerve Block (M-TAPA) on Postoperative Pain Relief in Laparoscopic Hysterectomy","Effectiveness of Modified-Thoracoabdominal Nerve Block With Perichondrial Approach (M-TAPA) on Postoperative Pain Relief in Laparoscopic Hysterectomy Surgery: A Prospective, Randomized, Double-Blind, Controlled Study","Inclusion Criteria:\n\n* Aged between 18 and 70 years\n* ASA (American Society of Anesthesiologists) physical status I, II, or III\n* Scheduled for elective laparoscopic hysterectomy\n* Voluntary participation with signed informed consent\n\nExclusion Criteria:\n\n* Hepatic or renal disease.\n* Coagulation disorders.\n* Uncontrolled cardiovascular or respiratory diseases.\n* Psychiatric disorders.\n* History of allergy to local anesthetics.\n* History of alcoholism, drug or substance abuse.\n* Body Mass Index (BMI) greater than 35 kg\u002Fm2\n* Refusal of the regional block procedure","18 Years",{"count":50,"type":21},60,"INTERVENTIONAL",[53],"NA","This study aims to investigate the effectiveness of a specific regional anesthesia technique, the Modified-Thoracoabdominal Nerve Block through a Perichondrial Approach (M-TAPA), on reducing pain after laparoscopic hysterectomy surgery. Hysterectomy is a common major surgical procedure, and managing postoperative pain is crucial for patient comfort and faster recovery.\n\nParticipants will be randomly assigned to one of two groups:\n\nThe M-TAPA Group: Patients will receive the nerve block using a local anesthetic (bupivacaine) before the surgery begins.\n\nThe Control Group: Patients will receive standard postoperative pain management without the nerve block.\n\nThe primary goal is to determine if the M-TAPA block reduces the total amount of opioid (morphine) used by patients in the first 24 hours after surgery. The researchers will also evaluate pain scores (NRS), the time until the first request for additional pain medication, patient satisfaction, and any side effects like nausea or vomiting",[56,25,57],"Postoperative Pain","Plane Blocks","2026-06-12",{"date":60,"type":32},"2026-06-16",{"date":62,"type":32},"2026-06-09",{"date":64,"type":21},"2026-11-15",{"name":66,"class":39},"Istinye University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":51,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":40},"100626042","effect-of-reading-a-personal-narrative-book-on-emotional-regulation-in-women-of-childbearing-age-undergoing-hysterectomy-relief-100626042","NCT07430488","Effect of Reading a Personal Narrative Book on Emotional Regulation in Women of Childbearing Age Undergoing Hysterectomy (RELIEF)","Effect of Reading a Personal Narrative Book on Emotional Regulation in Women of Childbearing Age Undergoing Hysterectomy: A Randomized Controlled Trial (RELIEF)","RELIEF","Inclusion Criteria:\n\n* Women aged 18 years or older and under 43 years of age\n* Patients with an indication for hysterectomy for a non-malignant condition\n* Patients who have provided explicit oral consent to participate\n* Patients covered by the French social security system\n* Patients able to read and understand French and capable of reading a French book within a timeframe compatible with the study schedule\n\nExclusion Criteria:\n\n* Women with suspected uterine cancer or high-grade dysplasia\n* Women participating or having participated to an interventional clinical trial within the 30 days prior to inclusion\n* Pregnant, breastfeeding, or parturient women\n* Protected patient: adults under guardianship or other legal protection; persons deprived of liberty by judicial or administrative order; persons hospitalized without consent\n* Patients with insufficient proficiency in the French language","42 Years",{"count":77,"type":21},156,[53],"The goal of this interventional clinical trial involving minimal risks and constraints is to evaluate whether an innovative approach to managing catastrophizing in the preoperative context of hysterectomy improves psychological outcomes compared to usual care in women of childbearing age who have been informed of an indication for hysterectomy.\n\nThe main questions it aims to answer are:\n\n* Does the use of a personal narrative book improve adaptive emotional regulation and reduce catastrophizing, anxiety, and depressive symptoms in the preoperative period?\n* Does this intervention improve postoperative patient satisfaction and reduce the need for additional supportive measures?\n\nResearchers will compare standard care (CNGOF information leaflet with psychological consultation if needed) with an intervention including a personal narrative book in addition to standard care, to see if the intervention improves emotional regulation, psychological well-being, and satisfaction.\n\nParticipants will:\n\n* provide explicit oral informed consent;\n* complete questionnaires on their emotional and psychological experience;\n* read a personal narrative book if they are randomized to the intervention group.",[25,81,82,83],"Anxiety","Depression","Catastrophizing","2026-06-04",{"date":86,"type":32},"2026-06-05",{"date":88,"type":32},"2026-05-13",{"date":90,"type":21},"2028-01",{"name":92,"class":39},"Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI)",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":51,"phases":105,"briefSummary":106,"conditions":107,"keywords":126,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":40},"100567703","stanford-program-to-accelerate-robotic-childrens-surgery-100567703","NCT06671639","Stanford Program to Accelerate Robotic Children's Surgery","SPARCS","Inclusion Criteria:\n\n1. Subject is between 6 - 21 years of age (weighing at least 15 kilograms)\n2. Subject clinically diagnosed with a medical condition for which one of the study procedures is appropriate therapy and selected as the treatment of choice by the guardian and surgeon.\n3. Subject without previous treatment using a robotic surgery device\n4. Subject or their guardian is willing and able to provide written informed consent\n5. Subject or their guardian is willing and able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Subject with uncorrected coagulopathy\n2. Subject has clinical requirement for primary open operative procedure\n3. Subject is ASA 4 or 5 status\n4. Subject is contraindicated for general anesthesia or surgery\n5. Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent\n6. Subject is pregnant or suspected to be pregnant","ALL","6 Years","21 Years",{"count":104,"type":21},250,[53],"The goal of this clinical trial is to provide additional data to confirm safety and performance of the da Vinci Xi Surgical System in a human clinical setting. This pilot study is intended to provide an initial assessment to evaluate the feasibility, safety, and effectiveness for the utilization of the da Vinci Xi on pediatric and adolescent patients. This clinical trial will be conducted under the auspices of Stanford University's IRB approval.",[108,109,110,25,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125],"Sleeve Gastrectomy","Cholecystectomy","Splenectomy","Endometriosis","Ureteral Re-implant","Cervical and Thoracic Tracheoplasty","Thymectomy","Lobectomy\u002FWedge Lung Resection","Lung Segmentectomy","Bronchoplasty","Endoscopic Laryngeal\u002FPharyngeal Suturing","Vocal Feminization","Laryngeal Cleft Repair","Endolaryngeal Adjacent Tissue Transfer","Pharyngoplasty","Ileocolonic Resections","Laryngoplasty","Proctectomy With Ileal Pouch-Anal Anastomosis",[127,128],"Robotic Surgery","Pediatric Robotic Surgery","2026-04-24",{"date":131,"type":32},"2026-04-30",{"date":133,"type":32},"2025-08-01",{"date":135,"type":21},"2028-02-28",{"name":137,"class":39},"Stanford University",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":100,"minAge":48,"maxAge":18,"enrollmentInfo":145,"targetDuration":4,"studyType":51,"phases":147,"briefSummary":150,"conditions":151,"keywords":157,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":40},"100592679","phase-2-exploring-the-impact-of-genetic-variations-on-the-clinical-efficacy-of-nalbuphine-in-postoperative-pain-management-100592679","NCT06996561","Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management","Nal","Inclusion Criteria:\n\n1. All adult men or women\n2. Age 18 to 70 years\n3. ASA criteria 1,2 and 3\n4. Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours\n\nExclusion Criteria:\n\n1. Surgical procedure duration lasting more than 4 hours\n2. Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine,\n3. History of hypersensitivity or allergy to opioids,\n4. Pregnant or breastfeeding mothers,\n5. History of narcotic dependency, addiction, and withdrawal\n6. Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission\n7. Refusing to participate in the study\n8. Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks",{"count":146,"type":21},263,[148,149],"PHASE2","PHASE3","The goal of this study is to identify the genes as well as their association with Nalbuphine. This will help the investigator to identify opioid vulnerability in Pakistani population in the postoperative patients and will contribute to overcoming the opioid crisis, resulting in better and safer outcomes.\n\nResearch question is:\n\nIs there any association between the underlying genetic variations and the analgesic efficacy of Nalbuphine in postoperative patients? The Research Objectives are\n\n1. To identify the underlying genes in postoperative patients having pain.\n2. To find an association between identified genes and nalbuphine clinical efficacy.\n\nProcedure: After the written informed consent adult men and women will be enrolled in the study. On the day of surgery in the preoperative area, a 5 ml blood sample will be drawn before surgery and will be sent to laboratory for analysis. After routine hemodynamic monitoring in the operative room, general anesthesia will be given including nalbuphine. Standard routine anesthesia monitoring will be done and maintained while monitoring heart rate, ECG, NIBP oxygen saturation, ETCO2 and temperature. Incremental analgesia will be provided whenever needed. After extubation and shifting to recovery room the 2nd sample of blood will be taken and will be sent for analysis. Pain score, nausea vomiting, sedation, requirement of analgesia will be assessed till 24 hours postoperatively.",[109,152,153,154,155,56,25,156],"Hernia, Abdominal","Appendectomy","Open Colorectal Surgery","Laparatomy","Cystectomy",[158,159,160,161],"genetic variations","nalbuphine","opioids","polymorphism","2026-04-14",{"date":164,"type":32},"2026-04-15",{"date":166,"type":32},"2025-09-01",{"date":168,"type":21},"2027-06-30",{"name":170,"class":39},"Dr. Asma Abdus Salam",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":179,"sex":16,"minAge":48,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":51,"phases":183,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100372519","phase-4-intraperitoneal-infusion-of-analgesic-for-postoperative-pain-management-100372519","NCT04130464","Intraperitoneal Infusion of Analgesic for Postoperative Pain Management","The Impact of the Continuous Infusion of Intraperitoneal Analgesics on Postoperative Pain After Minimally Invasive Hysterectomy: a Randomized Controlled Trial","ON-Q","Inclusion Criteria:\n\n* Hysterectomy planned for a benign gynecologic reason (no evidence of, or concern for, malignancy in the cervix, uterus, tubes or ovaries. Benign gynecologic reasons to have a hysterectomy include fibroids, abnormal uterine bleeding, endometriosis, and pelvic pain.)\n* Patient is scheduled to have surgery with a fellowship trained minimally invasive gynecologic surgeons at one of the study sites.\n* Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH).\n* Patient is capable of informed consent.\n* Patient is capable of completing the questionnaires.\n\nExclusion Criteria:\n\n* Concern for malignancy\n* The procedure is scheduled outside MIGS department.\n* Allergy to any study related medication (i.e. Ketorolac and Ropivacaine)\n* Patient is enrolled in another pain management study.",true,"65 Years",{"count":182,"type":21},120,[184],"PHASE4","The study is a prospective, double-blinded, placebo-controlled multi-center trial to measure if postoperative pain and the amount of narcotics used are reduced by a clinically significant amount in women undergoing minimally invasive hysterectomy receiving a continuous infusion of intraperitoneal (IP) local anesthetic (LA) or a continuous infusion of LA combined with an NSAID compared with a control group who receives only 0.9% normal saline.",[25,187,188,189],"Gynecologic Surgical Procedures","Narcotic Use","Pain, Postoperative",[191,192,193,194],"Intraperitoneal","Pain Pump","Ropivacaine","Ketorolac Tromethamine","2026-04-03",{"date":197,"type":32},"2026-04-09",{"date":199,"type":32},"2019-09-30",{"date":201,"type":21},"2026-12",{"name":203,"class":39},"Ying Liu",2,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":179,"sex":100,"minAge":48,"maxAge":180,"enrollmentInfo":211,"targetDuration":4,"studyType":51,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":40},"100617926","a-standardized-counseling-approach-to-preoperative-education-in-transmasculine-individuals-receiving-gender-affirming-surgery-100617926","NCT07324967","A Standardized Counseling Approach to Preoperative Education in Transmasculine Individuals Receiving Gender-affirming Surgery","Inclusion Criteria:\n\n* Any transgender or non-binary individual\n* Age 18-65\n* Assigned female at birth who desires a gender-affirming hysterectomy with or without oophorectomy\n* English-speaking\n\nExclusion Criteria:\n\n* Non-transgender individuals\n* Any transgender individual who has already had a bilateral oophorectomy\n* Any transgender person who was born without ovaries or a uterus\n* Non-English speaking",{"count":104,"type":21},[53],"The intervention will be an educational handout provided to a randomized cohort of patients that reviews the benefits and risks of retaining ovaries vs removing them. This educational handout will be provided prior to the surgical consultation at the time of the initial survey.",[25,215],"Gender Affirming Surgery","2026-04-02",{"date":195,"type":32},{"date":219,"type":32},"2026-03-12",{"date":221,"type":21},"2028-07-31",{"name":223,"class":39},"University of Minnesota",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":179,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":51,"phases":232,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":40},"100624763","vaginal-natural-orifice-transluminal-endoscopic-vnote-hysterectomy-with-uterosacral-suspension-100624763","NCT07413861","Vaginal Natural Orifice Transluminal Endoscopic (vNOTE) Hysterectomy With Uterosacral Suspension","VENUS","Inclusion Criteria:\n\n* Age\\>18\n* All women undergoing vNOTES hysterectomy ± Bilateral salpingectomy\u002Fsalpingo-oopherectomy for benign gynecological indication\n\nExclusion Criteria:\n\n* Exclusion for vNOTES surgery: pelvic inflammatory disease, previous rectal surgery, suspected malignancy, radiation\n* Indication for surgery: elvic prolapse\n* Other surgical interventions planned for the procedure",{"count":20,"type":21},[53],"As the adoption of Vaginal natural orifice transluminal endoscopic surgery (vNOTES) expands, attention is shifting from feasibility studies to the refinement of surgical steps that optimize long-term pelvic health.\n\nOne technical distinction between vNOTES hysterectomy and conventional laparoscopic or robotic hysterectomy is the routine early transection of the uterosacral ligaments as the approach is caudal-cephalic. These ligaments are not merely anatomic landmarks-they are the primary apical support structures of the vagina, anchoring the vaginal cuff to the sacrum and providing resistance against downward displacement. Disruption of this support can predispose patients to apical vaginal prolapse, a condition that significantly affects quality of life and may require complex reconstructive surgery.\n\nUterosacral ligament suspension (USLS) is a well-established, effective method of restoring apical support at the time of hysterectomy. Incorporating uterosacral suspension into vNOTES hysterectomy is a logical evolution toward ensuring that minimally invasive innovation does not come at the expense of long-term pelvic health. By adapting and standardizing this reconstructive step for vNOTES, surgeons can maintain apical support, reduce future prolapse risk, and uphold the same quality benchmarks established in laparoscopic and vaginal surgery.\n\nOBJECTIVE AND HYPOTHESIS:\n\nThis study aims to present a practical, reproducible technique for performing USLS in the vNOTES setting and to evaluate its potential immediate benefits, possible complication rates, and additional operative time compared with vNOTES hysterectomy without USLS. In doing so, we seek to demonstrate that preventive pelvic support can be seamlessly integrated without compromising the efficiency or advantages of the transvaginal endoscopic approach.",[235,25],"Prolapse Pelvic",[237,238,239,240,241,242],"hysterectomy","prevention","pelvic prolapse","uterosacral suspension","vaginal surgery","vaginal natural orifice transluminal surgery","NOT_YET_RECRUITING","2026-02-12",{"date":246,"type":32},"2026-02-17",{"date":248,"type":21},"2026-03-01",{"date":250,"type":21},"2027-12-01",{"name":252,"class":39},"The University of Texas Health Science Center, Houston",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":260,"targetDuration":262,"studyType":22,"phases":4,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100612962","comparison-of-sensory-block-coverage-and-clinical-effectiveness-of-tap-and-rectus-sheath-blocks-in-pfannenstiel-incisions-100612962","NCT07260396","Comparison of Sensory Block Coverage and Clinical Effectiveness of TAP and Rectus Sheath Blocks in Pfannenstiel Incisions","Comparison of the Cutaneous Sensory Block Coverage of Surgical Incisions and Clinical Effectiveness of TAP and Rectus Sheath Blocks in Total Abdominal Hysterectomies Performed With a Pfannenstiel Incision: A Prospective Observational Study","Inclusion Criteria:\n\n* ASA physical status I-II-III\n* Patients scheduled for elective total abdominal hysterectomy under general anesthesia and who have received either a preoperative rectus sheath block or a transversus abdominis plane block\n* Aged 18-70 years\n* Patients who agree to participate in the study and provide written informed consent\n\nExclusion Criteria:\n\n* Patients who refuse to participate\n* Patients who have not received any regional anesthesia technique\n* ASA physical status IV\n* Patients in whom unilateral or bilateral sensory spread is not observed following the bilaterally applied regional anesthesia technique\n* Patients who are uncooperative or have cognitive impairment or dementia\n* Patients with psychiatric disorders such as depression, mania, or schizophrenia, or those using antipsychotic medications for more than 4 weeks",{"count":261,"type":21},30,"1 Day","Hysterectomy is one of the most common major gynecologic surgeries performed for various indications, and hundreds of thousands of procedures are carried out annually, particularly in developed countries. In total abdominal hysterectomies, the Pfannenstiel incision is frequently preferred due to its advantages in terms of aesthetics, functionality, and postoperative recovery. However, this incision can cause significant postoperative pain because of the extensive cutaneous innervation of the lower abdominal wall. This pain may delay early mobilization and negatively affect patient comfort and satisfaction.\n\nAs part of multimodal analgesia strategies, regional anesthesia techniques are widely used in such surgeries to reduce opioid consumption and enhance analgesic efficacy. In this context, the Transversus Abdominis Plane (TAP) block and the Rectus Sheath Block (RSB) are among the effective techniques targeting the anterior abdominal wall, and various studies have investigated their spread patterns and clinical outcomes. However, data on the extent to which these blocks provide cutaneous sensory coverage of the Pfannenstiel incision remain limited, and direct comparative mapping studies are scarce in the literature.\n\nFor patients undergoing hysterectomy, regional anesthesia techniques are commonly applied perioperatively either as a single technique or in combination for pain management, with TAP and RSB being the most frequently used modalities. In addition, patient-controlled analgesia (PCA) devices are routinely employed as a component of multimodal pain management in this population.\n\nThe aim of this study is to comparatively evaluate the cutaneous sensory block areas produced by the TAP and RSB regional anesthesia techniques, their rates of coverage of the Pfannenstiel incision, and their clinical effectiveness.",[265,25],"Pain Management",[267,56,268],"Regional Anesthesia","Cutaneous Sensory Mapping","2025-11-21",{"date":271,"type":32},"2025-12-03",{"date":273,"type":21},"2026-01-01",{"date":275,"type":21},"2027-07-01",{"name":277,"class":39},"Samsun University",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":51,"phases":289,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":306},"100610917","day-care-in-robotic-surgery-hysterectomy-investigate-quality-of-life-and-safety-with-same-day-discharge-after-robotic-hysterectomy-for-patients-with-benign-and-malignant-disease-a-multicenter-randomized-study-with-3-hospitals-in-stockholm-sweden-100610917","NCT07233811","Day Care in Robotic Surgery Hysterectomy. Investigate Quality of Life and Safety With Same Day Discharge After Robotic Hysterectomy for Patients With Benign and Malignant Disease. A Multicenter Randomized Study With 3 Hospitals in Stockholm Sweden.","DARSH - A Multicenter Randomized Controlled Trial: Day-care vs Overnight Stay in Robotic Assisted Hysterectomy in Patients With Bening Disease and Endometrial Cancer.","DARSH","Inclusion Criteria:\n\n* Patient that are planned to undergo total robotic hysterectomy with or without adnexal surgery at the three sites.\n* Both benign conditions and endometrial cancer.\n* All BMI groups and all uterus sizes.\n\nExclusion Criteria:\n\n* Age not over 75 years old,\n* No company at home first night after surgery\n* ASA class 3 that is not only because of high BMI.\n* Simultaneous prolapse surgery\u002Flymph node evacuation.\n* Severe endometriosis or patients with chronic pain conditions that have a special pain regimen after surgery.","75 Years",{"count":288,"type":21},300,[53],"Patients undergoing robotic assisted hysterectomy in three different hospitals in Stockholm will be randomized to day-care (going home the same day as the surgery) or admission (staying at least one night after surgery). The aim with this study is to investigate if patients in day-care recover as fast\u002Ffaster as the other group that stays in the hospital. Both patients with benign disease and malign disease (endometrial cancer) will be included in the study.\n\nPatients quality of life (QoL) will be measured before surgery and after surgery at day 3,7 and 30 with a questionnaire called Eq-5D-5L from Euroqol. The questionnaire is validated for postoperative QoL and widely used.\n\nComplications due to surgery within the 30 first days after surgery will also be recorded in the two groups to make sure it is safe for the patients to go home the same day as their surgery.",[25,292,293],"Same Day Discharge","Robotic Surgical Procedures",[25,295,296,297],"Same day discharge","Robotic assisted Hysterectomy","Robotic suregery","2025-11-16",{"date":300,"type":32},"2025-11-18",{"date":302,"type":32},"2025-01-01",{"date":90,"type":21},{"name":305,"class":39},"Karolinska Institutet",3,{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":100,"minAge":48,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":51,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":40},"100519132","phase-3-nac-vs-placebo-on-opioid-use-for-hysterectomy-100519132","NCT06039566","NAC vs Placebo on Opioid Use for Hysterectomy","A Trial Evaluating the Impact of N-acetylcysteine on Opioid Use in Patients Undergoing a Hysterectomy Procedure","Inclusion\n\n* Undergoing elective laparoscopic or robotic, full, or partial hysterectomy procedure\n* 18 years of age and older\n\nExclusion\n\n* Less than 40kg in weight\n* Unable to provide written, informed consent\n* History of an adverse or anaphylactoid reaction to acetylcysteine\n* Active asthma, wheezing, or using inhaled bronchodilators\n* Non-English speaking\n* Insulin dependent diabetes if D5W is required\n* Blood clotting disorders",{"count":315,"type":21},240,[149],"This study will enroll females who are ages 18 and older undergoing a laparoscopic or robotic, partial or full hysterectomy. Participants will be randomized to receive IV n-acetylcysteine or placebo during the first 60 minutes of their procedure. At various time points after the procedure patients will be asked to report their pain scores, and any pain medication taken.",[25],[237],"2025-10-10",{"date":322,"type":32},"2025-10-14",{"date":324,"type":32},"2023-11-30",{"date":326,"type":21},"2026-12-09",{"name":328,"class":39},"Medical University of South Carolina",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":51,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":204},"100430570","vaginal-notes-hysterectomy-versus-vaginal-hysterectomy-100430570","NCT04886791","Vaginal NOTES Hysterectomy Versus Vaginal Hysterectomy","Vaginal Hysterectomy Versus Vaginal Assisted NOTES Hysterectomy (VANH): a Randomised Controlled Trial","VANH","Inclusion Criteria:\n\n* Written and orally given informed consent\n* 18 years and older\n* Native Dutch speaker or in control of the Dutch language in speaking and writing\n* Indication for hysterectomy for benign indication\n* Possible to perform a VH judged by experienced (resident) gynaecologist during gynaecological examination\n\nExclusion Criteria:\n\n* Any contra-indication for VH (for example, large uterus myomatosus, not enough descensus, etc) as judged by experienced gynaecologist\n* History of more than 1 caesarean section\n* History of endometriosis\n* History of rectal surgery\n* History of pelvic radiation\n* Suspected rectovaginal endometriosis\n* History of pelvic inflammatory disease, especially prior tubo-ovarian or pouch of Douglas abscess or suspected adhesions due to (ruptured) inflammatory disease (for example ruptured appendicitis)\n* Virginity\n* Pregnancy\n* Indication for anterior or posterior colporrhaphy during the same surgery\n* Indication of mid urethral slings\n* Uterus myomatosus will not be an exclusion criteria but the surgeon will indicate if it is possible to remove the uterus vaginally.",{"count":338,"type":21},124,[53],"Rationale: Natural orifice transluminal endoscopic surgery (NOTES) is a minimal invasive technique using the natural body orifices like stomach, oesophagus, bladder, rectum and vagina to access the human body for surgery. In 2012, the first vaginal NOTES (vNOTES) hysterectomy was performed. Potential benefits of vNOTES hysterectomy, also called the vaginal assisted NOTES hysterectomy (VANH) are no visible scars, less pain and a shorter hospital stay compared with laparoscopic hysterectomy as shown in the HALON trial. Up to now, no studies have compared the vNOTES hysterectomy with vaginal hysterectomy.\n\nObjective: The aim of this study is to compare the vNOTES hysterectomy with the vaginal hysterectomy for same day-discharge (SDD), complications, treatment related outcomes, post-operative recovery, quality of life and cost-effectiveness.\n\nStudy design: The study concerns a single-blinded, multicentre, randomised controlled trial.\n\nStudy population: Eligible women who fulfill the inclusion criteria and will undergo a hysterectomy for benign indication.\n\nIntervention: The study population will be randomly allocated to the VANH-group, who undergo a vaginal assisted NOTES hysterectomy (intervention group) or the vaginal hysterectomy group (control-group) and the participants will be single blinded. The pre- and postoperative care will be the same for both groups.\n\nMain study parameters\u002Fendpoints: Primary outcome is the percentage of patients that underwent the hysterectomy as in SDD setting. A total of 41 patients should be included in the control group and a total of 83 patients in the intervention group, using an enrollment ratio of 1:2, with an alpha of 0.05 and a power of 0.8.\n\nThe secondary outcomes are complications, treatment related outcomes, post-operative recovery, quality of life and cost-effectiveness.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness:\n\nvNOTES is a new surgical technique, but a combination of two existing techniques namely the vaginal hysterectomy and the laparoscopic hysterectomy. Only one randomized controlled trial has been published, comparing the total laparoscopic hysterectomy (TLH) with the VANH, which shows no inferiority of the vNOTES technique compared to a laparoscopy. A recent case series study has been published about the complication rate in VANH. There was a total complication rate in the hysterectomy group of 5.2%, in which 1.4% was intra-operative and 3.8% postoperative. Theoretically it is possible that the VANH causes less intra-operative complications because of an improved view during the procedure. No further literature is known about VH versus VANH. Participants of the study should fill in multiple questionnaires before randomization and postoperative about their general health, pain experience and used analgesics.",[25,342,343],"Natural Orifice Transluminal Endoscopic Surgery","Vaginal Hysterectomy",[345,346,335,347,25],"NOTES surgery","vNOTES","Vaginal hysterectomy","2025-08-13",{"date":350,"type":32},"2025-08-14",{"date":352,"type":32},"2021-07-05",{"date":354,"type":21},"2025-12-31",{"name":356,"class":39},"Zuyderland Medisch Centrum",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":364,"enrollmentInfo":365,"targetDuration":366,"studyType":22,"phases":4,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":384},"100602209","minimally-invasive-surgery-versus-open-radical-hysterectomy-in-presumably-early-stage-cervical-cancer-a-retrospective-multicenter-non-inferiority-study-comparing-overall-and-progression-free-survival-100602209","NCT07120529","Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective Multicenter Non-inferiority Study Comparing Overall and Progression-free Survival.","MOOSE","Inclusion Criteria:\n\nWomen undergoing radical hysterectomy type B or C according to the Querleu-Morrow classification for early-stage cervical cancer (FIGO stages IB1-IIA1, excluding FIGO IB3 between November 2018 and August 2025 Not using manipulator during surgery Vaginal cuff protective maneuver during surgery Conization before surgery (optional) SNB as a first stage of treatment (optional)\n\nExclusion Criteria:\n\nWomen undergoing surgery for advanced stage cervical cancer (FIGO \\>IIA1) or FIGO IB3 Metastasis detected in sentinel node biopsy (confirmed in ultrastaging) ECOG\\>2 Not willing to participate in the study Not willing to undergo CT-scans or gynecological examinations","85 Years",{"count":288,"type":21},"5 Years","The goal of this retrospective observational study with prospective follow-up is to compare the safety and treatment outcomes of radical laparoscopic hysterectomy (removal of the uterus with cervix) versus abdominal (open) hysterectomy performed after the publication of the LACC trial in women with early-stage cervical cancer.\n\nEligible participants will include adult, legally competent women diagnosed with early-stage cervical cancer (FIGO stages IB1-IIA1, excluding FIGO IB3) with negative sentinel lymph node biopsy (SNB) confirmed by ultrastaging.\n\nThe main questions it aims to answer are:\n\nIs there a difference in overall survival (OS) and progression-free survival (PFS) between laparoscopic and abdominal radical hysterectomy? Are postoperative complication rates and recurrence patterns comparable between the two surgical approaches?\n\nResearchers will compare outcomes in patients undergoing radical laparoscopic hysterectomy versus abdominal hysterectomy to assess differences in survival, complications, and recurrence.\n\nParticipants will:\n\nHave undergone radical hysterectomy (type B or C per Querleu-Morrow classification), preceded optionally by conization, with the use of uterine manipulators and absence of vaginal cuff protection explicitly excluded; Have had SNB as part of surgical staging; Be followed every 6 months for 5 years; Undergo clinical gynecologic examination and transvaginal and\u002For transabdominal ultrasound during follow-up; Undergo additional imaging (CT and\u002For pelvic MRI) in case of symptoms suggestive of recurrence.\n\nAll participants will follow standard post-treatment surveillance. No additional interventions beyond routine follow-up will be performed. Data on OS, PFS, complications (within 30 and 60 days postoperatively, classified by Clavien-Dindo), duration of surgery, recurrence site, and demographic characteristics will be collected.",[369,25],"Cervical Cancer",[371,372,373,374,375],"cervical cancer","radical laparoscopic hysterectomy","radical abdominal hysterectomy","protective maneuver","LACC study","2025-08-12",{"date":348,"type":32},{"date":379,"type":21},"2025-09-15",{"date":381,"type":21},"2030-12-01",{"name":383,"class":39},"Medical University of Silesia",5,{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":179,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":401,"locationsCount":4},"100601338","the-relationship-between-intraperitoneal-drain-placement-and-postoperative-pain-in-gynecologic-laparoscopy-100601338","NCT07109193","The Relationship Between Intraperitoneal Drain Placement and Postoperative Pain in Gynecologic Laparoscopy","Inclusion Criteria:\n\n* Elective procedure: Patients scheduled for elective pure laparoscopic gynecologic surgery (e.g., ovarian cystectomy, endometriosis resection, diagnostic laparoscopy).\n* ASA Physical Status: I-II (i.e., healthy or mild systemic disease).\n\nBMI: 18-35 kg\u002Fm².\n\nInformed Consent: Able and willing to give written consent and comply with postoperative pain assessments.\n\nExclusion Criteria:\n\n1 - Malignancy: Known or suspected gynecologic malignancy requiring staging or radical surgery.\n\n2\\. Conversion: Intraoperative conversion to laparotomy.\n\n3\\. Coagulopathy: Bleeding disorders or therapeutic anticoagulation that cannot be paused perioperatively.\n\n4\\. Prior Major Pelvic Surgery: ≥ 2 previous open abdominal operations (to avoid confounding from adhesions).\n\n5\\. Intra-Abdominal Infection: Active pelvic inflammatory disease or untreated urinary tract infection.\n\n6\\. Chronic Pain\u002FOpioid Use: Regular opioid use or chronic pelvic pain syndromes (endometriosis pain \\> 6 months).\n\n7\\. Allergy\u002FContraindication: Allergy to standard analgesics or contraindication to intraperitoneal drain placement (e.g., severe adhesions).",{"count":392,"type":21},76,"To assess the effect of intraperitoneal drain placement on postoperative pain after Gynecologic laparoscopy To evaluate whether the use of drains contributes to improved other clinical outcomes",[25],"2025-07-31",{"date":397,"type":32},"2025-08-07",{"date":166,"type":21},{"date":400,"type":21},"2027-10-01",{"name":402,"class":39},"Assiut University",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":51,"phases":411,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":40},"100590585","phase-3-topical-estrogen-brief-intervention-to-improve-postoperative-experience-for-transgender-men-undergoing-hysterectomy-100590585","NCT06969326","Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy","Inclusion Criteria:\n\n1. Gender diverse\u002Ftransgender men\n2. Age 18 or older\n3. Have been on testosterone for at least 6 months with plan to undergo gender-affirming hysterectomy and are willing to be randomized to the use of topical estrogen postoperatively.\n4. Have stable physical and mental health\n5. No contraindications to estrogen therapy\n6. Must be proficient in English or Spanish\n7. Must have access to a device to receive text messages for study follow up\n8. Must agree to allow their medical data to be used for research purposes\n\nExclusion Criteria:\n\n1. Under age 18\n2. Have not been on testosterone for at least 6 months prior to planned hysterectomy\n3. Known allergy to topical estrogen",{"count":410,"type":21},48,[149],"The purpose of this study is to determine if applying a single dose of topical estrogen cream in the operating room at the end of your hysterectomy (removal of uterus and cervix) improves the postoperative experience with bleeding and potential symptoms of dysphoria (a feeling of discomfort or distress). Topical estrogen cream is sometimes used if patients have increased risk of bleeding with surgery but is not currently utilized in a consistent way. This study aims to answer the question of whether this is a helpful treatment and should be included in standard postoperative care.",[414,415,25],"Postoperative Bleeding","Gender Dysphoria",[417,418,237],"gender dysphoria","gender affirmation","2025-05-08",{"date":421,"type":32},"2025-05-13",{"date":423,"type":32},"2025-05-01",{"date":425,"type":21},"2026-12-01",{"name":427,"class":39},"Women and Infants Hospital of Rhode Island",{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":16,"minAge":435,"maxAge":436,"enrollmentInfo":437,"targetDuration":4,"studyType":51,"phases":439,"briefSummary":440,"conditions":441,"keywords":444,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":40},"100575779","vnotes-and-vaginal-hysterectomy-for-benign-indications-100575779","NCT06776718","VNOTES and Vaginal Hysterectomy for Benign Indications","Comparison of VNOTES and Vaginal Hysterectomy for Benign Indications","Inclusion Criteria:\n\n* aged between 40 and 80 years\n* undergo hysterectomy for benign gynecological conditions\n\nExclusion Criteria:\n\n* history of urogynecological surgery (including pelvic organ prolapse surgery and mid-urethral sling procedures),\n* suspected gynecologic malignancies,\n* endometriosis,\n* tubal-ovarian abscesses,\n* pelvic organ prolapse exceeding grade 2,\n* individuals who refused to participate in the study","40 Years","80 Years",{"count":438,"type":21},100,[53],"This study aimed to compare the surgical outcomes of Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) and conventional vaginal hysterectomy (VH) for benign gynecological conditions.\n\nA prospective analysis will conducted at a tertiary hospital from January 2025 to February 2025. Patients aged 40-80 who underwent hysterectomy for benign indications will included. Outcomes will assessed included surgical outcomes, Visual Analog Scale (VAS) pain scores, and complication rates.",[25,442,443],"Hysterectomy, Benign Uterine Diseases","Hysterectomy, Vaginal",[346,445,446,447,448],"vaginal hysterectomy","benign gynecology","surgical outcomes","Pain","2025-01-13",{"date":451,"type":32},"2025-01-15",{"date":453,"type":21},"2025-01",{"date":455,"type":21},"2025-02",{"name":457,"class":458},"Dr. Lutfi Kirdar Kartal Training and Research Hospital","OTHER_GOV",{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":51,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":40},"100571355","phase-4-vaginal-cuff-anesthesia-and-post-operative-pain-medication-use-100571355","NCT06719180","Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use","A Prospective Randomized Controlled Trial of Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use","Inclusion Criteria:\n\n* Patients 18 years and older requiring total laparoscopic hysterectomy with or without bilateral salpingo-oophorectomy for benign conditions\n* Presence of malignancy\n\nExclusion Criteria:\n\n* Conversion to laparotomy\n\n  * Previous multiple abdominal and\u002For pelvic surgeries\n  * Significant medical comorbidities or cardiac history\n  * Poor initial Aldrete score4 (\\\u003C10)\n  * Significant pre-op pain medication use\n  * Contraindication to any medication that would be used in the study (Bupivacaine, epinephrine, tramadol or oxycodone)",{"count":438,"type":21},[184],"The purpose of this study is to determine whether an injection of a local anesthetic (Bupivacaine with epinephrine) in the vaginal cuff prior to closure would result in less immediate postoperative pain medication and increase patient comfort\u002Fsatisfaction.",[25,470],"Post Operative Analgesia","2025-01-06",{"date":473,"type":32},"2025-01-07",{"date":475,"type":32},"2024-12-01",{"date":477,"type":21},"2025-10-31",{"name":479,"class":39},"MediSys Health Network",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":100,"minAge":48,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":51,"phases":488,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":497,"leadSponsor":499,"locationsCount":4},"100571444","phase-4-comparative-study-between-the-analgesic-effect-of-dexmedetomidine-and-magnesium-sulfate-as-adjuvant-to-bupivacaine-using-ultrasound-guided-transversus-abdominis-plane-block-in-abdominal-hysterectomy--a-randomized-double-blinded-study-100571444","NCT06720337","Comparative Study Between the Analgesic Effect of Dexmedetomidine and Magnesium Sulfate as Adjuvant to Bupivacaine Using Ultrasound-Guided Transversus Abdominis Plane Block in Abdominal Hysterectomy : A Randomized Double-blinded Study","Inclusion Criteria:\n\n* ASA classification I-ll,\n* Aged \\>18 years,\n* weight 50-85 kg,\n* Patients who will undergo total abdominal hysterectomy\n\nExclusion Criteria:\n\n* • ASA classification I-ll,\n\n  * Aged \\>18 years,\n  * weight 50-85 kg,\n  * Patients who will undergo total abdominal hysterectomy",{"count":487,"type":21},64,[184],"Over 80% of patients who undergo surgery suffer from acute postoperative pain, with 75% of them rating the pain severity as moderate, severe, or extreme. Studies have shown that less than 50% of patients who undergo surgery report adequate relief from postoperative pain.\n\nAdditionally, if pain is not promptly managed after surgery, it can hinder a patient's ability to walk, potentially causing adverse effects such as thromboembolism, myocardial ischemia, and arrhythmia.\n\nThe opioid analgesics are most commonly used as parenteral agents to manage post operative pain but the problem of respiratory depression remains to be considered.\n\nThis study is designed to compare the analgesic effect between dexmedetomidine versus magnesium sulfate as adjuvant to bupivacaine using ultrasound guided Transversus Abdominis Plane block in patients undergoing abdominal hysterectomy",[25],[492],"ultrasound-Guided Transversus Abdominis Plane Block","2024-12-03",{"date":495,"type":32},"2024-12-06",{"date":302,"type":21},{"date":498,"type":21},"2026-02-01",{"name":402,"class":39},{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":179,"sex":16,"minAge":102,"maxAge":436,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":510,"conditions":511,"keywords":515,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":40},"100363639","evaluation-of-central-sensitization-fear-avoidance-and-pain-pressure-threshold-with-chronic-pain-after-hysterectomy-100363639","NCT04014829","Evaluation of Central Sensitization, Fear-Avoidance, and Pain-Pressure Threshold With Chronic Pain After Hysterectomy","Evaluation of Central Sensitization, Fear-Avoidance, and Pain-Pressure Threshold With Chronic Pain in Post-Hysterectomy Patients: A Collaborative Cohort Study (EPOCH - Enhancing Post-operative Outcomes in Chronic Pain After Hysterectomy)","EPOCH","Inclusion Criteria:\n\n* Age 21 to 80 years old\n* American Society of Anesthesiologists Physical Scale (ASA) I to III\n* Benign gynaecological indications for hysterectomy\n* Elective abdominal or laparoscopic hysterectomy\n\nExclusion Criteria:\n\n* Vaginal hysterectomy\n* Uterine prolapse, endometriosis, malignant disease, or pelvic pain as main indication for surgery\n* History of drug dependence or recreational drug use\n* History of chronic pain syndrome\n* Current chronic daily treatment with corticosteroids, excluding inhaled steroids\n* Allergy to study drugs\n* Major heart surgery\n* Heart transplant\n* Pacemaker inserted\n* Baseline non-sinus cardiac rhythm",{"count":509,"type":21},436,"Phase 1 (started in July 2019):\n\nCentral Sensitization Inventory (CSI), Fear-Avoidance Components Scale (FACS), pain-pressure threshold are factors associated with chronic post-hysterectomy pain (CPHP), but a complete understanding on the development of CPHP is lacking. The study aims to identify clinically-relevant factors for CPHP that can be reliably assessed preoperatively.\n\n===\n\nPhase 2 (anticipated start May 2022):\n\nIn addition to above factors, the association between heart rate variability (HRV) parameters, anxiety level, anticipated pain, and anticipated analgesia requirement with significant postoperative pain and CPHP will be investigated.",[25,512,513,514],"Chronic Pain","Central Sensitisation","Anxiety Depression",[25,512,516,517,518,519,520],"Fear-Avoidance","Central Sensitization","Pain-Pressure Threshold","Mechanical Temporal Summation","Heart rate variability","2024-11-24",{"date":523,"type":32},"2024-11-26",{"date":525,"type":32},"2019-07-23",{"date":527,"type":21},"2027-12",{"name":529,"class":458},"KK Women's and Children's Hospital",{"id":531,"slug":532,"hasResults":11,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":51,"phases":540,"briefSummary":541,"conditions":542,"keywords":545,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":40},"100562816","study-of-the-vascularization-of-the-vaginal-slice-after-total-laparoscopic-hysterectomy-using-indocyanine-green-injection-100562816","NCT06608082","Study of the Vascularization of the Vaginal Slice After Total Laparoscopic Hysterectomy, Using Indocyanine Green Injection.","Study of the Vascularization of the Vaginal Slice After Total Laparoscopic Hysterectomy, Using Indocyanine Green Injection. Prospective Feasibility Study","HYSTINDO","Inclusion Criteria:\n\n* Adult patient\n* Patient scheduled to undergo total hysterectomy through a surgically accessible laparoscopic procedure.\n* Patiente capable of providing informed consent to participate in the study.\n* Patiente covered by the Social Security system.\n\nExclusion Criteria:\n\n* Protected patient, under guardianship, curatorship or legal protection.\n* Patient's refusal or inadequate understanding of the French language.\n* Known allergy to iodine.\n* Ongoing pregnancy and breastfeeding.\n* Procedure requiring the use of indocyanine green.",{"count":539,"type":21},90,[53],"Hysterectomy is one of the most common surgical procedures in gynecology, especially by laparoscopy. Post-operative complications of hysterectomy are numerous and their causes are poorly understood.\n\nIndocyanine green is a fluorescent dye that, when exposed to infrared light, makes it possible to visualize the vascularization by fluorescence.\n\nThe project consists in studying the vascularization of the vaginal cuff after total laparoscopic hysterectomy using the injection of indocyanine green. This is a prospective feasibility study.\n\nDuring the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence. The fluorescence values will be compared to the occurrence or absence of postoperative complications.\n\nThis is the first study using this imaging technique combined with indocyanine green in this surgery. This study will employ a novel objective sequential fluorescence analysis software that has already proven its effectiveness in digestive surgery. The sequential measurement of the change in fluorescence intensity visualized in the images of laparoscopy will enable the production of vaginal perfusion graphs using a video modeling tool such as the TRACKER software. This software measures the evolution of green levels in a region of interest, from which a time-fluorescence curve can be obtained. The presence of fluorescence will be defined by a fluorescence intensity value of Fmax-Fmin on the graph.",[25,543,544],"Vascularization","Complication of Surgical Procedure",[546,547,548,549,550],"indocyanine green","laparoscopic hysterectomy","Post-operative complications of hysterectomy","TRACKER software","imaging technique","2024-09-20",{"date":553,"type":32},"2024-09-23",{"date":555,"type":21},"2024-09-21",{"date":557,"type":21},"2025-11-30",{"name":559,"class":39},"University Hospital, Clermont-Ferrand",{"id":561,"slug":562,"hasResults":11,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":51,"phases":569,"briefSummary":570,"conditions":571,"keywords":575,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":586},"100465197","does-additional-use-of-preoperative-azithromycin-decrease-posthysterectomy-infections-100465197","NCT05337566","Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections","Infections After Hysterectomy - a Placebo-controlled Study Comparing the Prophylactic Use of Azithromycin and Cefuroxime With Single Cefuroxime","Inclusion Criteria:\n\n* Women undergoing hysterectomy for benign indication in University Hospitals (Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital and Kuopio University Hospital) who have not any contraindications for azithromycin or cefuroxime.\n\nExclusion Criteria:\n\n* Inability to understand the study protocol.\n* Allergy for either cefuroxime or azithromycin.\n* Congenital or acquired prolonged Q-T-corrected interval. All the participants will be asked about arrhythmias and whether they have congenital arrhythmias in the family,\n* Electrocardiogram will be checked for all the participants.\n* Use of medicines that may prolong Q-T-corrected interval (class Ia arrhythmia medications, quinidine, procainamide, and class III arrhythmia medications dofetilide, amiodarone and sotalol).\n* Use of selective serotonin reuptake inhibitor medication and prolonged Q-T-corrected interval.",{"count":568,"type":21},2278,[53],"During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.",[572,25,573,574],"Infection Post Op","Antibiotics","Prophylactic",[576],"postoperative, infection, hysterectomy, antibiotics","2024-08-19",{"date":579,"type":32},"2024-08-21",{"date":581,"type":32},"2022-09-05",{"date":583,"type":21},"2030-12",{"name":585,"class":39},"Helsinki University Central Hospital",6,{"id":588,"slug":589,"hasResults":11,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":595,"targetDuration":4,"studyType":51,"phases":597,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":609,"locationsCount":4},"100551088","superior-hypogastric-plexus-block-during-laparoscopic-hysterectomy-subtle-100551088","NCT06455540","SUperior Hypogastric Plexus Block During Laparoscopic hysterEctomy (SUBTLE)","Superior Hypogastric Plexus Block During Laparoscopic Hysterectomy","SUBTLE","Inclusion Criteria:\n\n* Able to provide informed consent\n* Undergoing laparoscopic hysterectomy for benign indications\n\nExclusion Criteria:\n\n* Planned procedure that requires dissection of the presacral space\n* Allergy to block medication (s)\n* Known or suspected malignancy",{"count":596,"type":21},198,[53],"This trial sest to assess the efficacy of a superior hypogastric plexus block (SHPB) for quality of recovery after a laparoscopic hysterectomy.",[25],[25,601,602],"Minimally invasive surgery","Quality of recovery","2024-06-13",{"date":605,"type":32},"2024-06-14",{"date":607,"type":21},"2024-07-16",{"date":354,"type":21},{"name":610,"class":39},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":612,"slug":613,"hasResults":11,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":180,"enrollmentInfo":619,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":620,"conditions":621,"keywords":622,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":4},"100471613","long-term-outcomes-after-laparoscopic-subtotal-and-total-hysterectomy-100471613","NCT05421156","Long-term Outcomes After Laparoscopic Subtotal and Total Hysterectomy","Evaluation of Long-term Sexual Dysfunctions, Urinary Dysfunctions and Pelvic Organ Prolapse in Women Who Underwent Laparoscopic Subtotal Versus Total Hysterectomy for Benign Conditions","LAST-1","Inclusion Criteria:\n\n* Women who underwent subtotal or total hysterectomy by laparoscopy for benign conditions.\n\nExclusion Criteria:\n\n* Women with gynecological and non-gynecological cancers.",{"count":438,"type":21},"Hysterectomy is one of the most commonly performed gynecologic surgeries in the USA. It is used for many benign conditions such as leiomyoma and abnormal uterine bleeding. Surgery may involve the removal of the cervix (total hysterectomy, TH) or its preservation (supracervical or subtotal hysterectomy, SH). Whether TH or SH is the best procedure for benign conditions is a matter of debate. Considering the lack of evidence, this study aims to evaluate long-term sexual dysfunctions, urinary dysfunctions and pelvic organ prolapse in women who underwent laparoscopic subtotal versus total hysterectomy for benign conditions.",[25],[623,624,25],"Subtotal Laparoscopic Hysterectomy","Total Laparoscopic Hysterectomy","2022-10-31",{"date":627,"type":32},"2022-11-02",{"date":629,"type":21},"2024-07",{"date":631,"type":21},"2028-07",{"name":633,"class":39},"University of Palermo"]